News, Infos & good to know Forum: Community User: Lirumlarum1

Merck's Keytruda has annual sales of 13 billion just for lung cancer. What would their sales be if had treatment for pancreatic cancer ? Another 1 to 2 billion? NK/IBRX will have it all . BCG Lung cancer breast cancer, Pancreatic cancer HIV vaccine/cure Covid-19 vaccine/cure IBRX will be better than MERCK and will sport a higher market cap than merck at 190 billion in a few years! At today's pps of only 30.92 NK/IBRX is super cheap for what it will grow into. Nk mkt cap is 3.366 and IBRX is 12 billion. Potential to double that prior to merger!

Patrick Soon Shiong on Twitter, 3 hours ago: "Great explanation of all the weapons we were born with to fight #COVID especially with inevitable evolution and mutations. Memory B , memory T and Antibodies. Well done article by Katherine. Our vaccine deigned to activate these weapons #VaccineforSouthAfrica" Patrick Soon Shiong's on fire, and so am I!!! 🔥💥🌋

With a CR rate of 72%, N-803 has met its primary endpoint with 59% probability of CR patients maintaining CR for at least 12 months. With the observed strong efficacy and an SAE rate of 1%, N-803 represents a novel treatment option for BCG unresponsive CIS with a favorable benefit:risk ratio, in a therapeutically challenging disease. Clinical trial information: NCT03022825 https://meetinglibrary.asco.org/record/195299/abstract

Dr. Pat Soon-Shiong on Twitter, 18 min. ago: Dr. Karim Chamie from UCLA presenting #NMIBC #Bladder #CIS cancer data @ASCO GU 2021. 71% complete remission @immunitybio #Anktiva #N803

BlackRock Inc. reports 56.81% increase in ownership of NK / NantKwest, Inc. 2021-02-05 - BlackRock Inc. has filed a 13F-HR form disclosing ownership of 3,303,410 shares of NantKwest, Inc. (US:NK) with total holdings valued at $44,033,000 USD as of 2020-12-31. BlackRock Inc. had filed a previous 13F-HR on 2020-11-06 disclosing 2,106,648 shares of NantKwest, Inc. at a value of $14,609,000 USD. This represents a change in shares of 56.81 percent and a change in value of 201.41 percent during the quarter. https://fintel.io/so/us/nk/blackrock

NantKwest on Twitter, 23 hours ago: Most current COVID-19 vaccines are designed to protect against symptoms; we need to prevent transmission to enable herd immunity, so we need vaccines that prevent the virus from replicating. That’s where T cells come in: Antibodies block, T cells kill. https://mobile.twitter.com/nantkwest?lang=de

ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity https://nantkwest.com/category/press-releases/

NantKwest on Twitter, 1 hour ago: "Coronavirus vaccines may be administered in PILL form in the future @iosBioPharma #oralvaccine" https://t.co/GYOYNfmKK5?amp=1

Auch möchte ich nochmal darauf hinweisen, dass NantKwest und ImmunityBio in Partnerschaft mit iosbio auch an einer Covidimpfung in Pillenform arbeiten, welche auch schon im der Erprobung ist. "The #COVID19 #oralvaccine candidate targets both the mutation prone spike protein and more stable nucleocapsid protein." "Nadhim Zahawi, vaccines minister, has said the Government is assessing “technologies with pills” being developed around the globe. US-based ImmunityBio is using UK-developed technology to create vaccines in a pill or tablet form - and has started clinical trials. IosBio, based in Sussex, has engineered a vaccine in oral form and carried out initial trials on monkeys. It is said to have produced “highly effective” results." https://www.google.com/amp/s/www.express.co.uk/news/uk/1394796/coronavirus-vaccines-nahim-zahawi-astrazeneca-clinical-trials-iosbio-immunitybio-ont/amp

Soon Shiong on Twitter, one hour ago: "Need new approaches to vaccine design. Not sure that adding S antibody vaccine to another S antibody vaccine will work. Maybe adding T cell to B cell makes more sense. Use the ENTIRE immune system. We know how to do this today in cancer"

Auch wenn es bis zum fertigen Impfstoff noch etwas dauern kann, wäre das schon ein echter Hammer, wenn man nur weiß, wie der Impfstoff aufgebaut sein muss, um gegen mögliche, neue Mutationen wirksam zu sein und auch einen entsprechenden Langzeitschutz bieten kann.

Und jetzt gerade der nächste Hammer: Patrick Soon Shiong on Twitter, one minute ago: "Genomic sequencing of virus. South Africa leads the world and now able to answer a question that affects all of humanity" Das hört sich so an, als ob Soon Shiong/ImmunityBio/NantKwest die Antwort haben! Oh man, ich freue mich so auf dir nächsten Wochen! 😃

Der Satz "Very disturbing but sadly not unexpected when the focus is just to block the virus" verrät, dass er nicht die eigene/unsere Vaccine meint! Denn er betonte schon mehr als ein mal: "Antibodies block, T cells kill"

Patrick Soon Shiong on Twitter, one hour ago: South African study finds that current vaccines which produces antibodies to block the virus is no longer effective against the new escape Covid mutants. Very disturbing but sadly not unexpected when the focus is just to block the virus #Covid_19 Need to rethink vaccine design

@iosBioPharma 5. Feb. Our Chairman, @waynechannon , spoke to @MTatalovic at @ResFortnight about our partnership with @immunitybio, and the ongoing trials in South Africa and the US. The #COVID19 #oralvaccine candidate targets both the mutation prone spike protein and more stable nucleocapsid protein. https://mobile.twitter.com/immunitybio